Literature DB >> 10508233

Prostanoid receptors: structures, properties, and functions.

S Narumiya1, Y Sugimoto, F Ushikubi.   

Abstract

Prostanoids are the cyclooxygenase metabolites of arachidonic acid and include prostaglandin (PG) D(2), PGE(2), PGF(2alpha), PGI(2), and thromboxne A(2). They are synthesized and released upon cell stimulation and act on cells in the vicinity of their synthesis to exert their actions. Receptors mediating the actions of prostanoids were recently identified and cloned. They are G protein-coupled receptors with seven transmembrane domains. There are eight types and subtypes of prostanoid receptors that are encoded by different genes but as a whole constitute a subfamily in the superfamily of the rhodopsin-type receptors. Each of the receptors was expressed in cultured cells, and its ligand-binding properties and signal transduction pathways were characterized. Moreover, domains and amino acid residues conferring the specificities of ligand binding and signal transduction are being clarified. Information also is accumulating as to the distribution of these receptors in the body. It is also becoming clear for some types of receptors how expression of their genes is regulated. Furthermore, the gene for each of the eight types of prostanoid receptor has been disrupted, and mice deficient in each type of receptor are being examined to identify and assess the roles played by each receptor under various physiological and pathophysiological conditions. In this article, we summarize these findings and attempt to give an overview of the current status of research on the prostanoid receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508233     DOI: 10.1152/physrev.1999.79.4.1193

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  601 in total

Review 1.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.

Authors:  Paola Castagnino; Devashish Kothapalli; Elizabeth A Hawthorne; Tina Xu; Richard K Assoian
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-05-10       Impact factor: 3.072

3.  Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation.

Authors:  Racquel Domingo-Gonzalez; Carol A Wilke; Steven K Huang; Yasmina Laouar; Jeanette P Brown; Christine M Freeman; Jeffrey L Curtis; Gregory A Yanik; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

4.  Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  J Bioanal Biomed       Date:  2011-01-10

5.  Prostaglandin E(2) is crucial in the response of podocytes to fluid flow shear stress.

Authors:  Tarak Srivastava; Ellen T McCarthy; Ram Sharma; Patricia A Cudmore; Mukut Sharma; Mark L Johnson; Lynda F Bonewald
Journal:  J Cell Commun Signal       Date:  2010-04-08       Impact factor: 5.782

6.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

7.  Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation.

Authors:  Abdullah Shafique Ahmad; Yun Tai Yun; Muzamil Ahmad; Takayuki Maruyama; Sylvain Doré
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 8.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

9.  Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors.

Authors:  S Ayabe; T Murata; T Maruyama; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

10.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.